29 related articles for article (PubMed ID: 15858856)
1. Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model.
Peng J; Ladumor MK; Unadkat JD
Drug Metab Dispos; 2022 May; 50(5):613-623. PubMed ID: 35149540
[TBL] [Abstract][Full Text] [Related]
2. Effects of Phytochemical P-Glycoprotein Modulators on the Pharmacokinetics and Tissue Distribution of Doxorubicin in Mice.
Kim TH; Shin S; Yoo SD; Shin BS
Molecules; 2018 Feb; 23(2):. PubMed ID: 29414892
[TBL] [Abstract][Full Text] [Related]
3. Compartmental models for apical efflux by P-glycoprotein--part 1: evaluation of model complexity.
Nagar S; Tucker J; Weiskircher EA; Bhoopathy S; Hidalgo IJ; Korzekwa K
Pharm Res; 2014 Feb; 31(2):347-59. PubMed ID: 24019023
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral bioanalysis methods of tissues and body biofluids.
DiFrancesco R; Maduke G; Patel R; Taylor CR; Morse GD
Bioanalysis; 2013 Feb; 5(3):351-68. PubMed ID: 23394701
[TBL] [Abstract][Full Text] [Related]
5. Regulation of P-glycoprotein by human immunodeficiency virus-1 in primary cultures of human fetal astrocytes.
Ashraf T; Ronaldson PT; Persidsky Y; Bendayan R
J Neurosci Res; 2011 Nov; 89(11):1773-82. PubMed ID: 21826700
[TBL] [Abstract][Full Text] [Related]
6. The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.
Lan X; Kiyota T; Hanamsagar R; Huang Y; Andrews S; Peng H; Zheng JC; Swindells S; Carlson GA; Ikezu T
J Neuroimmune Pharmacol; 2012 Jun; 7(2):412-23. PubMed ID: 21826404
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of transgenic mouse models for conditional gene knockout in the blood-brain and blood-CSF barriers.
Crouthamel MH; Kelly EJ; Ho RJ
Transgenic Res; 2012 Feb; 21(1):113-30. PubMed ID: 21538071
[TBL] [Abstract][Full Text] [Related]
8. A novel MDR1 GT1292-3TG (Cys431Leu) genetic variation and its effect on P-glycoprotein biologic functions.
Crouthamel MH; Wu D; Yang Z; Ho RJ
AAPS J; 2010 Dec; 12(4):548-55. PubMed ID: 20623213
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.
Fujimoto H; Higuchi M; Watanabe H; Koh Y; Ghosh AK; Mitsuya H; Tanoue N; Hamada A; Saito H
Biol Pharm Bull; 2009 Sep; 32(9):1588-93. PubMed ID: 19721237
[TBL] [Abstract][Full Text] [Related]
10. Drug interactions at the blood-brain barrier: fact or fantasy?
Eyal S; Hsiao P; Unadkat JD
Pharmacol Ther; 2009 Jul; 123(1):80-104. PubMed ID: 19393264
[TBL] [Abstract][Full Text] [Related]
11. Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.
Hassan HE; Myers AL; Coop A; Eddington ND
J Pharm Sci; 2009 Dec; 98(12):4928-40. PubMed ID: 19370547
[TBL] [Abstract][Full Text] [Related]
12. MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells.
Eilers M; Roy U; Mondal D
Exp Biol Med (Maywood); 2008 Sep; 233(9):1149-60. PubMed ID: 18535159
[TBL] [Abstract][Full Text] [Related]
13. Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors.
Shaik N; Pan G; Elmquist WF
J Pharm Sci; 2008 Dec; 97(12):5421-33. PubMed ID: 18393290
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein.
Obradovic T; Dobson GG; Shingaki T; Kungu T; Hidalgo IJ
Pharm Res; 2007 Feb; 24(2):318-27. PubMed ID: 17180728
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic considerations in the treatment of CNS tumours.
Motl S; Zhuang Y; Waters CM; Stewart CF
Clin Pharmacokinet; 2006; 45(9):871-903. PubMed ID: 16928151
[TBL] [Abstract][Full Text] [Related]
16. The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice.
Salama NN; Kelly EJ; Bui T; Ho RJ
J Pharm Sci; 2005 Jun; 94(6):1216-25. PubMed ID: 15858856
[TBL] [Abstract][Full Text] [Related]
17. Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats.
Savolainen J; Edwards JE; Morgan ME; McNamara PJ; Anderson BD
Drug Metab Dispos; 2002 May; 30(5):479-82. PubMed ID: 11950774
[TBL] [Abstract][Full Text] [Related]
18. Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier.
Cutler L; Howes C; Deeks NJ; Buck TL; Jeffrey P
J Pharm Sci; 2006 Sep; 95(9):1944-53. PubMed ID: 16850390
[TBL] [Abstract][Full Text] [Related]
19. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
Kim RB; Fromm MF; Wandel C; Leake B; Wood AJ; Roden DM; Wilkinson GR
J Clin Invest; 1998 Jan; 101(2):289-94. PubMed ID: 9435299
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
